Glioblastoma multiform treatment market Size 2013-2017 | Forecast 2018-2024

Glioblastoma multiform is the high-grade glioma and potent malignant brain tumor that affects glial cells. Glioblastoma multiform contains the complexly differentiated neoplastic astrocytes which are the subtype of central nervous system. Glioblastoma multiform is different from the anaplastic astrocytoma due to the presence of hyperplastic blood vessels and necrotic tissue. The glioblastoma multiform is diagnosed by using the imaging modules namely, Positron Emission Tomography (PET), Magnetic Resonance Imaging (MRI), and Computed Tomography (CT). Glioblastoma multiform is classified into two types namely, gliosarcoma and giant cell glioblastoma. Gliomas are the tumors emerge from glial cells and might occur in brain or the spinal cord. The common symptoms observed in the patients suffering from glioblastoma multiform include nausea, headache, seizure, memory loss, and hemiparesis, among others.

The global glioblastoma multiform treatment market is growing at a significant CAGR due to increase in the geriatric population, and changes in the lifestyle. The increase in alcohol consumption, a rise in malaria prevalence, and the increase in the incidence of seizures are the key factors driving the global glioblastoma multiform treatment market. In addition to that, increased R & D in gene therapy, molecular biotechnology for the treatment of CNS associated disorders, urgent need of alternative treatment procedures due to the resistance of glioma cells to conventional therapies are anticipated to boost the glioblastoma multiform treatment market. However, major restraints of the glioblastoma multiform treatment market are current treatment therapies such as radiation and chemotherapy does not prevent tumor recurrence that causes death in glioblastoma multiform patients. Similarly, high expenditure for the genomics-based research, less number of drugs available in the market, and the high cost of treatment are expected to hinder the glioblastoma multiform treatment market growth.

Free sample of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/global-glioblastoma-multiforme-treatment-market/#ulp-4H8Z4LpNMLEuOnnx

The global Glioblastoma multiform treatment market is divided into following categories-
1. Drug type
• Temozolomide
• Bevacozumab
• carmustine
• Radiosensitizers
• Others

2. End-users
Hospital, retail and online pharmacies

Free TOC of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/global-glioblastoma-multiforme-treatment-market/#ulp-c654SbFYO64MsOhu

And lastly on the basis of geographical regions, the glioblastoma multiform treatment market segmented into following regions- North America, Asia-Pacific, Europe, the Middle East & Africa, and Latin America. North America dominates the glioblastoma multiform treatment market followed by Europe and Asia-Pacific. North America region growth is attributed to increase in the prevalence of glioblastoma multiform disease (According to Centers for Disease Control and Prevention (CDC), in 2011, approximately 22,000 adults in the U.S. were diagnosed with primary malignant tumors of the brain and spinal cord out of which gliomas accounted for the highest rate of incidence), investments in research and development, and increasing CNS cancers in aging population. Company’s betting heavily on research activities due to lack of drugs to treat glioblastoma multiform in the market. Similarly, National Brain Tumor Society, Brain Tumor Foundation of Canada, and American Brain Tumor Association are the health organizations engaged in raising awareness about glioblastoma multiform leads to the growth of glioblastoma multiform treatment market. Europe glioblastoma multiform treatment market revenue growth is driven by increase in geriatric population, change in lifestyle and increase in research and development activities by various pharmaceutical companies. Asia-Pacific is expected to be the fastest growing market due to improved healthcare infrastructure, and rising awareness of glioblastoma multiform treatment. Furthermore, extensive use of genomic profiling in bioinformatics technology by the research and development firms in Asia-Pacific region is expected to drive the treatment market for nervous carcinoma by discovering the new drug targets.

Ask Analyst for Full Information about this report @
https://www.precisionbusinessinsights.com/market-reports/global-glioblastoma-multiforme-treatment-market/#ulp-14mlyhjMGhVjZqa3

Some of the key players in glioblastoma multiform treatment market are Merck & Co Inc. (U.S.), Teva Pharmaceutical Industries, Ltd. (Israel), Arbor Pharmaceuticals LLC. (U.S.), Sun Pharmaceutical Industries, Ltd. (India), F. Hoffmann-Le Roche Ltd. (Switzerland), Abbvie, Inc. (U.S.), Celldex Therapeutics, Inc. (U.S.), Exellixis, Inc. (U.S.), Bristol-Myers Squibb Co. (U.S.), AstraZeneca (U.K.), GlaxoSmithKline plc. (U.K.), CANbridge Life Sciences Ltd. (China), Apogenix (Germany), Pfizer, Inc. (U.S.), and Vascular Biogenics (Israel) to name a few. In 2015, CANbridge Life Sciences acquired license for to develop, manufacture and commercialize Apogenix’s APG101 onco-immunotherapy in glioblastoma for China.

Increase in prevalence of brain tumors (According to U.S. National Cancer Institute (NCI) glioblastoma multiform is considered as the most aggressive form of brain cancer with 15.4% of all primary brain tumors and about 60% – 75% of all astrocytoma) driving the growth of glioblastoma multiform treatment market. Moreover, various drugs under clinical trials like CDX-110 (manufactured by Celldex Therapeutics) (Phase 3) and DCVax (Northwest Biotherapeutics) (Phase 3) expected to fuel growth of glioblastoma multiform treatment market. Rising product approvals from USFDA also expected to drive revenue of glioblastoma treatment market. For e.g. in 2005, USFDA approved Temozolomide (Temodar) capsules, developed by Schering Corporation (Merck & Co., Inc.) to treat newly diagnosed patients with glioblastoma multiform disease associated with radiotherapy and then as maintenance treatment. Similarly, entry of generics into the market also increases the growth of glioblastoma multiform treatment market. For instance, in 2013, Teva Pharmaceutical Industries Ltd, and Sun Pharmaceutical Industries Ltd. entered the market with the generic version of Temozolomide.

Get access to full summary @
https://www.precisionbusinessinsights.com/market-reports/global-glioblastoma-multiforme-treatment-market/